Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L. & Habener, J. F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl Acad. Sci. USA 84, 3434–3438 (1987).
Google Scholar
Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300–1304 (1987).
Google Scholar
Drucker, D. J. & Holst, J. J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66, 1765–1779 (2023).
Google Scholar
Drucker, D. J. GLP-1-based therapies for diabetes, obesity and beyond. Nat. Rev. Drug Discov. 24, 631–650 (2025).
Google Scholar
Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406, 2257–2268 (2025).
Google Scholar
Gonzalez-Rellan, M. J. & Drucker, D. J. New molecules and indications for GLP-1 medicines. JAMA 334, 1231–1234 (2025).
Google Scholar
Lingvay, I. et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13, 935–948 (2025).
Google Scholar
Wharton, S. et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13, 949–963 (2025).
Google Scholar
Aroda, V. R. et al. High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial. Diabetes Care 48, 905–913 (2025).
Google Scholar
Frias, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
Google Scholar
Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26–36 (2025).
Google Scholar
Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705–719 (2023).
Google Scholar
Wharton, S. et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N. Engl. J. Med. 393, 1077–1087 (2025).
Google Scholar
Overgaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A. & Drucker, D. J. Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep. Med. 2, 100387 (2021).
Google Scholar
Hannon, T. S. et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 406, 1484–1496 (2025).
Google Scholar
Ravussin, E. et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 37, 1060–1074 e1064 (2025).
Google Scholar
Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873–1888 (2024).
Google Scholar
Borner, T. et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 70, 2545–2553 (2021).
Google Scholar
Knop, F. K. et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes. Metab. 26, 5474–5478 (2024).
Google Scholar
Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48, 846–859 (2025).
Google Scholar
Lilly Investors. Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated/ (2025).
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
Google Scholar
Kosiborod, M. N. et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404, 949–961 (2024).
Google Scholar
Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427–437 (2025).
Google Scholar
Lam, C. S. P. et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity 33, 1645–1656 (2025).
Google Scholar
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
Google Scholar
Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089–2099 (2025).
Google Scholar
Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
Google Scholar
Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391, 1573–1583 (2024).
Google Scholar
Bonaca, M. P. et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405, 1580–1593 (2025).
Google Scholar
Rossing, P. et al. Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. Diabetes Care 48, 1878–1887 (2025).
Google Scholar
Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30, 2849–2856 (2024).
Google Scholar
Drucker, D. J. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 36, 338–353 (2024).
Google Scholar
Malhotra, A. et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 391, 1193–1205 (2024).
Google Scholar
Drucker, D. J. The benefits of GLP-1 drugs beyond obesity. Science 385, 258–260 (2024).
Google Scholar
Jara, M. et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat. Med. 31, 3128–3140 (2025).
Google Scholar
Rasouli, N. et al. Benefit of semaglutide in symptomatic peripheral artery disease by baseline type 2 diabetes characteristics: insights from STRIDE, a randomized, placebo-controlled, double-blind trial. Diabetes Care 48, 1529–1535 (2025).
Google Scholar
McGowan, B. M. et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 12, 631–642 (2024).
Google Scholar
Jastreboff, A. M. et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 392, 958–971 (2025).
Google Scholar
Thomas, M. K. et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 106, 388–396 (2021).
Google Scholar
Tang, H. et al. Glucagon-like peptide-1 receptor agonists and risk of Parkinson’s disease in patients with type 2 diabetes: a population-based cohort study. Mov. Disord. 39, 1960–1970 (2024).
Google Scholar
Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664–1675 (2017).
Google Scholar
Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson’s disease. J. Clin. Invest. 123, 2730–2736 (2013).
Google Scholar
McGarry, A. et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 23, 37–45 (2024).
Google Scholar
Meissner, W. C., Remy, P., Giordana, C., Maltete, D. & Derkinderen, P. Trial of lixisenatide in early Parkinson’s disease. N. Engl. J. Med. 390, 1176–1185 (2024).
Google Scholar
Vijiaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405, 627–636 (2025).
Google Scholar
Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582–590 (2020).
Google Scholar
Koychev, I. et al. Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial. Alzheimers Res. Ther. 16, 212 (2024).
Google Scholar
Maretty, L. et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat. Med. 31, 267–277 (2025).
Google Scholar
Battini, V. et al. Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues. J. Neurol. 271, 3417–3425 (2024).
Google Scholar
Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951–962 (2025).
Google Scholar
Edison, P. et al. Evaluation of liraglutide in the treatment of Alzheimer’s disease. Alzheimers Dement. 17, e057848 (2021).
Google Scholar
Cummings, J. L. et al. Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimers Res. Ther. 17, 14 (2025).
Google Scholar
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression; https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462 (24 February 2025).
Svensson, P. A. et al. Non-alcohol substance use disorder after bariatric surgery in the prospective, controlled Swedish Obese Subjects study. Obesity 31, 2171–2177 (2023).
Google Scholar
Lahteenvuo, M. et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry 82, 94–98 (2025).
Google Scholar
Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).
Google Scholar
Wang, W. et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol. Psychiatry 29, 2587–2598 (2024).
Google Scholar
Farokhnia, M. et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J. Clin. Invest. https://doi.org/10.1172/JCI188314 (2025).
Hendershot, C. S. et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 82, 395–405 (2025).
Google Scholar
Lengsfeld, S. et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine 57, 101865 (2023).
Google Scholar
Probst, L. et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight 8, e170419 (2023).
Google Scholar
Bruns Vi, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L. & Farokhnia, M. IUPHAR review – glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharm. Res. 207, 107312 (2024).
Google Scholar
Dawed, A. Y. et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 11, 33–41 (2023).
Google Scholar
Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020).
Google Scholar
German, J. et al. Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery. Nat. Med. 31, 2269–2276 (2025).
Google Scholar
Cifuentes, L. et al. Genetic and physiological insights into satiation variability predict responses to obesity treatment. Cell Metab. 37, 1655–1666 (2025).
Google Scholar
Tzoulis, P. & Baldeweg, S. E. Semaglutide for weight loss: unanswered questions. Front. Endocrinol. 15, 1382814 (2024).
Google Scholar
Ryan, D. H. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat. Med. 30, 2049–2057 (2024).
Google Scholar
Heni, M. et al. Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study. Diabetologia 68, 1666–1673 (2025).
Google Scholar
Squire, P., Naude, J., Zentner, A., Bittman, J. & Khan, N. Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis. BMJ Open 15, e089477 (2025).
Google Scholar
Baggio, L. L. et al. GLP-1 receptor expression within the human heart. Endocrinology 159, 1570–1584 (2018).
Google Scholar
Hathaway, J. T. et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 142, 732–739 (2024).
Google Scholar
Shor, R. et al. Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Ophthalmol. 143, 587–594 (2025).
Google Scholar
Imbroane, M. R., LeMoine, F. & Nau, C. T. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am. J. Obstet. Gynecol. 233, 116.e1–116.e7 (2025).
Google Scholar
Hanif, M. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes. Am. J. Cardiol. 246, 10–13 (2025).
Google Scholar
Dao, K. et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 14, e083550 (2024).
Google Scholar
Kindel, T. L. et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg. Endosc. 39, 180–183 (2025).
Google Scholar
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C. & Sun, E. C. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA 331, 1672–1673 (2024).
Google Scholar
Wadden, T. A. et al. Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials. JAMA Intern. Med. 184, 1290–1300 (2024).
Google Scholar
Ueda, P. et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern. Med. 184, 1301–1312 (2024).
Google Scholar
Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. 30, 168–176 (2024).
Google Scholar
Hurtado, I., Robles, C., Peiro, S., Garcia-Sempere, A. & Sanfelix-Gimeno, G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia 67, 2471–2480 (2024).
Google Scholar
Shapiro, S. B. et al. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ 388, e080679 (2025).
Google Scholar
Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).
Google Scholar
Conte, C., Hall, K. D. & Klein, S. Is weight loss-induced muscle mass loss clinically relevant? JAMA 332, 9–10 (2024).
Coskun, T. et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 13, 674–684 (2025).
Google Scholar
Lundgren, J. R. et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N. Engl. J. Med. 384, 1719–1730 (2021).
Google Scholar
Scott Butsch, W. et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes. Pillars 15, 100186 (2025).
Google Scholar
Frias, J. P. et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402, 720–730 (2023).
Google Scholar
Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med 389, 877–888 (2023).
Google Scholar
Enebo, L. B. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397, 1736–1748 (2021).
Google Scholar
Rosenstock, J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529–544 (2023).
Google Scholar
Kizilkaya, H. S. et al. Characterization of genetic variants of GIPR reveals a contribution of beta-arrestin to metabolic phenotypes. Nat. Metab. 6, 1268–1281 (2024).
Google Scholar
Veniant, M. M. et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat. Metab. 6, 290–303 (2024).
Google Scholar
le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162–173 (2024).
Google Scholar
Davies, M. J. et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N. Engl. J. Med. 393, 648–659 (2025).
Google Scholar
Garvey, W. T. et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N. Engl. J. Med. 393, 635–647 (2025).
Google Scholar
Wean, J. et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Mol. Metab. 95, 102074 (2025).
Google Scholar
Gutgesell, R. M. et al. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nat. Metab. 7, 1282–1298 (2025).
Google Scholar
Liu, C. M. et al. GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice. Nat. Metab. 7, 1266–1281 (2025).
Google Scholar
Braca, S. et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: a prospective pilot study. Headache 65, 1831–1838 (2025).
Google Scholar
Dahl, K. et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet 406, 149–162 (2025).
Google Scholar
Jastreboff, A. M. et al. Once-monthly maridebart cafraglutide for the treatment of obesity – a phase 2 trial. N. Engl. J. Med. 393, 843–857 (2025).
Google Scholar
Rosenstock, J. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N. Engl. J. Med. 393, 1065–1076 (2025).
Google Scholar
McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001–2012 (2025).
Google Scholar
Tamborlane, W. V. et al. Liraglutide in children and adolescents with type 2 diabetes. N. Engl. J. Med. 381, 637–646 (2019).
Google Scholar
Tamborlane, W. V. et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care 45, 1833–1840 (2022).
Google Scholar
Arslanian, S. A. et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N. Engl. J. Med. 387, 433–443 (2022).
Google Scholar
Kelly, A. S. et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N. Engl. J. Med. 382, 2117–2128 (2020).
Google Scholar
Weghuber, D. et al. Once-weekly semaglutide in adolescents with obesity. N. Engl. J. Med. 387, 2245–2257 (2022).
Google Scholar
Mathieu, C. et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39, 1702–1710 (2016).
Google Scholar
Shah, V. N. et al. Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid. 4, EVIDoa2500173 (2025).
Google Scholar
Pasqua, M. R. et al. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat. Med. 31, 1239–1245 (2025).
Google Scholar
Dejgaard, T. F. et al. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 26, 4905–4915 (2024).
Google Scholar
Source link
